Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.
Scope of this research
*
In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot
*
Antihormonal therapy sales forecasts for brands and generics from 2008 to 2018
*
Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
*
Evaluation of the strategies of leading players in the antihormonals market
Research and analysis highlights
The antihormonals market was worth $6.9 billion in 2008 across the seven major pharmaceutical markets. Its growth within the next decade, at a marginal CAGR of 0.1%, will be predominantly limited by patent expiries of leading brands.
In 2008, Arimidex (anastrozole; AstraZeneca), Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca) were the three leading antihormonal brands in terms of sales. These will remain the top three brands through to 2018, even though Arimidex and Casodex will lose around 40% of their brand value due to generic competition.
In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2008, with an antihormonals portfolio valued at over $3.4 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.
Key reasons to purchase this research
*
Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2008 to 2018
*
Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth
*
Benchmark the antihormonal therapy cancer brands against generics and rest of class and align their 7MM performance with a rest of world snapshot
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/Market-Research-Reports/Commercial-Insight-Antihormonal-Cancer-Therapies-Stagnant-sales-indicative-of-a-mature-market.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: http://bharatbookresearch.blogspot.com
Follow us on twitter: http://twitter.com/3bbharatbook |
